Wholesale

The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX^™. The efficacy of CANNIDEX^™ has not been confirmed by FDA-approved research and CANNIDEX^™ is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX^™.

CANNIDEX^™ is a trademark of Cannidex Brands, LLC. Direct Effects™ is a trademark of AfGin Pharma, LLC.

CANNIDEX^™ Brands, LLC is a licensee of United States Patent Application No. 62126757, filed in March 2015 by inventor Ronald Aung-Din and currently pending with the USPTO. This patent covers the application of topical hemp derived CBD at the back-of-the-neck (BON) region through Direct Effects™. No FDA-approved clinical trials have been conducted with any Direct Effects™ CBD topical formulation.